In context
Brilacidin is a peptide mimetic investigated for antimicrobial activity. One study examined resistant gonococcal strains and infection-related cell models. [1]
At a glance
- Type
- Non-peptide compound / mimetic
- Regulatory context
- The cited source describes research, not a determination of present marketing authorisation. Country, formulation and indication must be checked separately.
- Evidence
- Activity against bacteria in the laboratory does not establish a clinical treatment for gonorrhoea or permission to substitute for evidence-based care.
How to interpret this evidence
Activity against bacteria in the laboratory does not establish a clinical treatment for gonorrhoea or permission to substitute for evidence-based care. [1]
Safety and clinical context
The evidence described here does not establish safety for unsupervised use. Product identity, route, formulation, interactions and long-term effects cannot be inferred from a study category.
Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.
Primary sources
Read the underlying source and its limitations. A study citation does not by itself establish efficacy or approval.
- A novel peptide mimetic, brilacidin, for combating multidrug-resistant Neisseria gonorrhoeae. pubmed.ncbi.nlm.nih.gov